C-reactive Protein for Predicting Cardiovascular and All-Cause Mortality in Type 2 Diabetic Patients: A Meta-Analysis

Ran Tian,Mingliang Tian,Liang Wang,Hai Qian,Shuyang Zhang,Haiyu Pang,Zhenyu Liu,Ligang Fang,Zhujun Shen
DOI: https://doi.org/10.1016/j.cyto.2019.02.005
IF: 3.926
2019-01-01
Cytokine
Abstract:There is interest in using blood C-reactive protein (CRP) to predict adverse prognosis outcomes patients with type 2 diabetes. This meta-analysis aimed to investigate the association between elevated baseline CRP level and unfavorable outcomes in type 2 diabetes patients. PubMed and Embase databases were systematically searched for studies on the association of elevated baseline CRP level with cardiovascular mortality and all-cause mortality from their inception to July 2018. Pooled risk ratio (RR) with 95% confidence intervals (CI) was calculated for the highest versus the lowest CRP level. Six prospective cohort studies and two post hoc analyses of randomized controlled trials involving 22,322 type 2 diabetes patients were included. Meta-analysis indicated that type 2 diabetes patients with the highest CRP level had a greater risk of all-cause mortality (RR 2.03; 95% CI 1.49–2.75) and cardiovascular mortality (RR 1.76; 95% CI 1.46–2.13). Subgroups analysis indicated that the increased cardiovascular and all-cause mortality risk was consistently found in different study design, follow-up duration or patients with or without cardiovascular risk/established cardiovascular disease subgroups. This meta-analysis indicates that elevated baseline serum CRP level is independently associated with future cardiovascular and all-cause mortality in type 2 diabetes patients.
What problem does this paper attempt to address?